SCM
PTCT icon

Soleus Capital Management’s PTC Therapeutics PTCT Stock Holding History

Soleus Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,300
Closed -$727K – 67
2020
Q1 		$727K Buy
16,300
+9,500
+140% +$478K 0.85% 28
2019
Q4 		$326K Buy
+6,800
New +$289K 0.31% 44

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Soleus Capital Management's PTCT Position: Q2 2020 in Review

Soleus Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2020, closing a stake of 16,300 shares — an estimated $727K sold.

Soleus Capital Management first reported a position in PTCT in Q4 2019 and held it in 2 quarters. The position peaked at $727K in Q1 2020. 203 funds tracked by Wall St. Rank hold PTCT as of Q2 2020.

  • Soleus Capital Management reported no remaining PTC Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Soleus Capital Management sold 16,300 PTC Therapeutics shares in Q2 2020, an estimated $727K.
  • Soleus Capital Management first reported a position in PTC Therapeutics in Q4 2019 and held it in 2 quarters.
  • Soleus Capital Management's PTC Therapeutics position peaked at $727K in Q1 2020.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2020.

Based on Soleus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.